The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment

Journal of Medical Virology

Volumn 73, Issue 3, 2004, Pages 392-396

  Pradat, Pierre ^a   Maynard, Marianne ^a   Buti, Maria ^b   Berthillon, Pascale ^c   Picchio, Gaston ^d   Tillmann, Hans L ^e   Wiegand, Johannes ^e   Voirin, Nicolas ^a   Manns, Michael P ^e   Esteban, Juan Ignacio ^b   Martinot, Michèle ^f   Marcellin, Patrick ^f   Trepo, Christian ^a,c  

^a HÔTEL DIEU   (France)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c INSERM   (France)

^d Ortho McNeil Pharmaceutical Incorporated   (United States)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f BEAUJON HOSPITAL   (France)

Author keywords

HCV core antigen; HCV RNA; Prediction of treatment response

Indexed keywords

HEPATITIS C ANTIGEN; HEPATITIS C CORE ANTIGEN; PEGINTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ARTICLE; BIOASSAY; DRUG RESPONSE; HEPATITIS C; HEPATITIS C VIRUS CORE ANTIGEN TEST; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; PREDICTION; RELAPSE; VIREMIA;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIGENS; HUMANS; INTERFERON ALFA-2B; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL CORE PROTEINS; VIREMIA;

HEPATITIS C VIRUS;

EID: 2542446368     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20104     Document Type: Article

References (21)

1. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S. 2003. Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy. Hepatology 37:600-609.
2. Bouvier-Alias M, Patel K, Dahari H, Beaucourt S, Larderie P, Blatt L, Hezode C, Picchio G, Dhumeaux D, Neumann AU, McHutchison JG, Pawlotsky JM. 2002. Clinical utility of total HCV core antigen quantification: A new indirect marker of HCV replication. Hepatology 36:211-218.
3. Civeira M-P, Prieto J. 1999. Early predictors of response to treatment in patients with chronic hepatitis C. J Hepatol 31(Suppl 1):237-243.
4. Detmer J, Lagier R, Flynn J, Zayati C, Kolberg J, Collins M, Urdea M, Sanchez-Pescador R. 1996. Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. J Clin Microbiol 34:901-907.
5. French Consensus Conference, Paris, February 2002. 2002. Treatment of Hepatitis C. Recommendations. Med Sci 18:375-382.
6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goņales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982.
7. Komatsu F, Takasaki K. 1999. Determination of serum hepatitis C virus (HCV) core protein using a novel approach for quantitative evaluation of HCV viraemia in anti-HCV positive patients. Liver 19:375-380.
8. Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL, Pockros PJ, Haussinger D, Smith CI, Lin A, Pappas SC. 2002. Prognostic factors and early predictability of sustained viral response with peginterferon α-2a (40 kDa). J Hepatol 37:500-506.
9. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358:958-965.
10. Maynard M, Pradat P, Berthillon P, Picchio G, Voirin N, Martinot M, Marcellin P, Trepo C. 2003. Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients response to therapy. J Viral Hepat 10:318-323.
11. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. 1998. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485-1492.
12. McHutchison JG, Shad JA, Gordon SC, Morgan TR, Ling M-H, Garaud JJ, Albrecht JK, Dienstag JL. 2001. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. J Viral Hepat 8:414-420.
13. National Institutes of Health Consensus Development Conference Statement. 2002. Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 36(Suppl 1):S3-S20.
14. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht JK. 1998. Randomised trial of interferon α-2b plus ribavirin for 48 weeks versus interferon α-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432.
15. Poynard T, McHutchison J, Goodman Z, Ling M-H, Albrecht J. 2000. Is an "à la carte" combination interferon α-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 31:211-218.
16. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. 1993. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 74:1093-1102.
17. Tanaka E, Kiyosawa K, Matsumoto A, Kashiwakuma T, Hasegawa A, Mori H, Yanagihara O, Ohta Y. 1996. Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon α. Hepatology 23:1330-1333.
18. Tong MJ, Hwang SJ, Lefkowitz M, Lee SD, Co RL, Conrad A, Schmid P, Lo KJ. 1994. Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin. J Gastroenterol Hepatol 9:587-591.
19. Veillon P, Payan C, Picchio G, Maniez-Montreuil M, Guntz P, Lunel F. 2003. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and Amplicor Monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy. J Clin Microbiol 41:3212-3220.
20. Zanetti AR, Romano L, Brunetto M, Colombo M, Bellati G, Tackney C. 2003. Total HCV core antigen assay: A new marker of hepatitis C viremia for monitoring the progress of therapy. J Med Virol 70:27-30.
21. Zeuzem S, Lee J-H, Franke A, Rüster B, Prümmer O, Herrmann G, Roth WK. 1998. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon α. Hepatology 27:1149-1156.